Use of Demineralised Bone Matrix (DBX) in Osteochondritis Dissecans (OCD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01283737|
Recruitment Status : Withdrawn
First Posted : January 26, 2011
Last Update Posted : June 26, 2012
This is a 1:1 randomised pilot study in 30 patients in 1 site in Helsinki, Finland.
The investigators hypothesize that function, pain, type and quality of cartilage in adult patients with osteochondritis dissecans of the knee will be better in the DBX group compared to the mosaicplasty group.
|Condition or disease||Intervention/treatment||Phase|
|Osteochondritis Dissecans||Device: DBX Putty Procedure: Mosaicplasty||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Subject-blind, Controlled Pilot Trial to Evaluate the Effectiveness and Safety of the Use of Demineralized Bone Matrix (DBX®) Versus Mosaicplasty in the Treatment of Late-Stage Osteochondritis Dissecans (OCD) of the Knee in Patients With a Mature Skeleton|
DBX Putty in glass syringe
Device: DBX Putty
OCD of the knee will be treated with DBX Putty
|Active Comparator: Mosaicplasty||
Mosaicplasty procedure performed to treat OCD of the knee
- Change of Brittberg-Peterson functional assessment score from baseline until 12 months post-op [ Time Frame: At enrollment (day -7), at full weight-bearing (6-8 weeks post-operative), 6 months post-operative, 12 months post-operative ]Score 0-130 (see Clin Orthop Relat Res 2000 May;374:212-34) to assess function and pain
- Type and quality of the formed cartilage to assess the effectiveness of the treatment [ Time Frame: 12 months post-operative ]The type and quality of the newly formed cartilage will be assessed with arthroscopy and/or MRI /dGEMRIC)
- Number of patients with complications to assess the safety of the use of the treatment [ Time Frame: Enrolment (day -7) until 12 months post-operative ]All adverse events and complications will be recorded throughout the trial and assessed for severity and causality.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01283737
|Principal Investigator:||Jari Salo, MD||Töölö Hospital|